10-Q: Salarius Pharmaceuticals Reports First Quarter 2024 Results Amid Strategic Review and Cost-Cutting Measures

Salarius Pharmaceuticals reported a net loss of $1.7 million for the first quarter of 2024, while implementing cost-saving measures and exploring strategic alternatives.

Summary

• Salarius Pharmaceuticals reported a net loss of $1.7 million for the first quarter of 2024, compared to a $5.3 million loss in the same period of 2023.
• The company's research and development expenses significantly decreased to $243,002 from $3.7 million year-over-year due to cost-saving measures.
• General and administrative expenses also saw a slight decrease to $1.5 million from $1.7 million in the prior year.
• As of March 31, 2024, Salarius had $4.4 million in cash and cash equivalents.
• The company is exploring strategic alternatives and has implemented cost-saving measures to extend its cash runway into the first half of 2025.
• Salarius is focused on developing treatments for cancers caused by dysregulated gene expression, with two drug candidates: SP-3164 and seclidemstat (SP-2577).
• The company has an accumulated deficit of $78.1 million as of March 31, 2024.
• The company's ongoing clinical trials include an investigator-initiated trial at MD Anderson Cancer Center (MDACC) studying SP-2577 in combination with azacitidine for the treatment of patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML).

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges and uncertainty about the company's future, despite some positive clinical data. The cost-cutting measures and exploration of strategic alternatives suggest a company under pressure.

Positives

• The net loss decreased significantly year-over-year, from $5.3 million to $1.7 million.
• Research and development expenses were substantially reduced due to cost-saving measures.
• The company has extended its cash runway into the first half of 2025 through cost-saving measures.
• The company has a 60% objective response rate in Ewing sarcoma first-relapse patients treated with seclidemstat, topotecan and cyclophosphamide (TC).
• The company has expanded its intellectual property portfolio with composition-of-matter protection into 2039 for its novel molecular glue.

Negatives

• The company continues to operate at a loss, with a net loss of $1.7 million for the quarter.
• The company has an accumulated deficit of $78.1 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may need to pursue a dissolution and liquidation if it does not complete a strategic transaction or obtain financing.
• The company has significantly reduced its expenditures on operational and research and development activities.

Risks

• The company's ability to continue as a going concern is uncertain, and it may need to pursue dissolution and liquidation if it cannot secure additional funding or a strategic transaction.
• There are uncertainties regarding the timing and results of additional clinical data from ongoing clinical trials evaluating seclidemstat.
• The exploration of strategic alternatives may not result in a definitive transaction or enhance stockholder value.
• The company's cost-saving initiatives may not be successful and may not increase stockholder value.
• The company faces challenges in preserving capital and may incur unanticipated charges.
• The company has limited financial, personnel, and other operating resources.
• The company is dependent on contract research organizations, vendors, and investigators.
• The company's ability to remain listed on Nasdaq is uncertain.

Future Outlook

The company expects to continue to incur significant expenses and operating losses. It is exploring strategic alternatives and may seek additional capital through equity or debt financing, collaborations, or by reducing expenditures. The company believes its current cash is sufficient to fund operations into the first half of 2025.

Management Comments

• The company is exploring strategic alternatives to maximize return for investors, which includes selling or out licensing SP-3164 and/or SP-2577 to a third party.
• The company has significantly reduced costs in both programs.
• The company plans to evaluate information from the investigator-initiated trial at MDACC and that data to augment its ongoing work in seeking strategic alternatives.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focused on developing treatments for cancers with high unmet medical needs. The company's focus on targeted protein inhibitors and degraders aligns with current trends in cancer therapeutics. The company's financial challenges are not uncommon for clinical-stage biopharmaceutical companies, which often require significant capital to fund research and development.

Comparison to Industry Standards

• Salarius's cash position of $4.4 million is relatively low compared to other publicly traded clinical-stage biopharmaceutical companies, many of which have tens or hundreds of millions in cash reserves.
• The company's R&D spending of $243,002 for the quarter is significantly lower than many of its peers, reflecting its cost-cutting measures and limited resources. For example, companies like Kura Oncology or Relay Therapeutics spend tens of millions per quarter on R&D.
• The 60% objective response rate in Ewing sarcoma patients is promising, but it is based on a small sample size and needs to be validated in larger trials. Companies like Deciphera Pharmaceuticals have seen similar early positive results in their clinical trials.
• The company's exploration of strategic alternatives is a common strategy for companies facing financial challenges, similar to what companies like Agenus or Verastem have done in the past.
• The company's accumulated deficit of $78.1 million is typical for a clinical-stage biotech company that has not yet generated revenue from product sales. Many companies in this sector have accumulated deficits in the hundreds of millions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders face the risk of significant dilution if the company raises additional capital through equity offerings.
• Employees have been impacted by cost-saving measures, including the reduction in workforce and changes in executive roles.
• The company's ability to continue its research and development programs may be impacted by its financial challenges, potentially affecting patients who could benefit from its therapies.
• The company's suppliers and vendors may be impacted by the company's cost-cutting measures and financial uncertainty.

Next Steps

• The company will continue to explore strategic alternatives.
• The company will evaluate information from the MDACC trial related to hematological cancers.
• The company will continue to implement cost-saving measures.
• The company may seek additional capital through equity or debt financing.
• The company may consider new collaborations or selectively partnering its technology.

Key Dates

Keywords

Salarius Pharmaceuticals, seclidemstat, SP-2577, SP-3164, Ewing sarcoma, cancer treatment, clinical trials, protein degrader, LSD1 inhibitor, strategic alternatives, cost savings, biopharmaceutical, hematologic cancers, financial results